Details

Autor(en) / Beteiligte

• Schneider, Marie
• Rolfs, Clara
• Trumpp, Matthias
• Winter, Susann
• Fischer, Luise
• Richter, Mandy
• Menger, Victoria
• Nenoff, Kolja
• Grieb, Nora
• Metzeler, Klaus H
• Kubasch, Anne Sophie
• Sockel, Katja
• Thiede, Christian
• Wu, Jincheng
• Woo, Janghee
• Brüderle, Andreas
• Hofbauer, Lorenz C
• Lützner, Jörg
• Roth, Andreas
• Cross, Michael
• Platzbecker, Uwe

Titel

Activation of distinct inflammatory pathways in subgroups of LR-MDS

Ist Teil von

• Leukemia, 2023-08, Vol.37 (8), p.1709-1718

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Aberrant innate immune signaling has been identified as a potential key driver of the complex pathophysiology of myelodysplastic neoplasms (MDS). This study of a large, clinically and genetically well-characterized cohort of treatment-naïve MDS patients confirms intrinsic activation of inflammatory pathways in general mediated by caspase-1, interleukin (IL)-1β and IL-18 in low-risk (LR)-MDS bone marrow and reveals a previously unrecognized heterogeneity of inflammation between genetically defined LR-MDS subgroups. Principal component analysis resolved two LR-MDS phenotypes with low (cluster 1) and high (cluster 2) levels of IL1B gene expression, respectively. Cluster 1 contained 14/17 SF3B1-mutated cases, while cluster 2 contained 8/8 del(5q) cases. Targeted gene expression analysis of sorted cell populations showed that the majority of the inflammasome-related genes, including IL1B, were primarily expressed in the monocyte compartment, consistent with a dominant role in determining the inflammatory bone marrow environment. However, the highest levels of IL18 expression were found in hematopoietic stem and progenitor cells (HSPCs). The colony forming activity of healthy donor HSPCs exposed to monocytes from LR-MDS was increased by the IL-1β-neutralizing antibody canakinumab. This work reveals distinct inflammatory profiles in LR-MDS that are of likely relevance to the personalization of emerging anti-inflammatory therapies.